{"denomUnitsSelected":"Participants","description":"Kaplan-Meier methodology will be used to estimate the distribution of\\>\\>\\> TTP.","reportingStatus":"NOT_POSTED","timeFrame":"Time between date the patient initiated sapanisertib and disease progression, assessed up to 2 years","title":"Time to Progression (TTP) in Crossover Patients (Phase II)","type":"OTHER_PRE_SPECIFIED"}